Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy

Frontiers in Immunology
Raquel TarazonaRafael Solana

Abstract

Natural killer (NK) cells participate in the early immune response against melanoma and also contribute to the development of an adequate adaptive immune response by their crosstalk with dendritic cells and cytokine secretion. Melanoma resistance to conventional therapies together with its high immunogenicity justifies the development of novel therapies aimed to stimulate effective immune responses against melanoma. However, melanoma cells frequently escape to CD8 T cell recognition by the down-regulation of major histocompatibility complex (MHC) class I molecules. In this scenario, NK cells emerge as potential candidates for melanoma immunotherapy due to their capacity to recognize and destroy melanoma cells expressing low levels of MHC class I molecules. In addition, the possibility to combine immune checkpoint blockade with other NK cell potentiating strategies (e.g., cytokine induction of activating receptors) has opened new perspectives in the potential use of adoptive NK cell-based immunotherapy in melanoma.

References

Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M KirkwoodR H Blum
Mar 5, 1998·Nature·V M BraudA J McMichael
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M B AtkinsS A Rosenberg
Sep 20, 2001·Proceedings of the National Academy of Sciences of the United States of America·A CerwenkaL L Lanier
Feb 6, 2002·The Journal of Experimental Medicine·Franca GerosaGiorgio Trinchieri
Mar 29, 2002·The Journal of Investigative Dermatology·Claudia S VetterJürgen C Becker
Aug 13, 2003·The Journal of Experimental Medicine·Cristina BottinoAlessandro Moretta
Dec 31, 2003·Trends in Immunology·Megan A CooperMichael A Caligiuri
Sep 3, 2004·The New England Journal of Medicine·Hensin TsaoArthur J Sober
Sep 24, 2004·British Journal of Cancer·C S VetterJ C Becker
Nov 9, 2004·Trends in Immunology·Lorenzo MorettaAlessandro Moretta
Apr 12, 2005·Nature Immunology·Tal I ArnonOfer Mandelboim
Feb 18, 2006·Cancer Immunology, Immunotherapy : CII·Rafael SolanaRaquel Tarazona
Aug 17, 2006·Genes & Development·Lynda ChinDavid E Fisher
Aug 22, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Laurent DerréNadine Gervois
Nov 2, 2007·The Journal of Investigative Dermatology·Emanuela CagnanoAngel Porgador
Dec 25, 2007·Cytokine & Growth Factor Reviews·Evelyn UllrichLaurence Zitvogel
Apr 8, 2009·The Journal of Clinical Investigation·Tadepally LakshmikanthFrancesco Colucci
Jun 17, 2009·The Journal of Experimental Medicine·Cameron S BrandtSteven D Levin
Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Annette PaschenSelma Ugurel
Oct 24, 2009·Experimental Dermatology·Jürgen C BeckerRalph A Reisfeld
Jul 14, 2010·Cancer Immunology, Immunotherapy : CII·Federico GarridoAngel M García-Lora
Jul 27, 2010·Trends in Immunology·Shannon BurkeEnnio Carbone
Jan 13, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Giulia FregniAnne Caignard
Mar 9, 2011·Immunology and Cell Biology·Beatriz Sanchez-CorreaRaquel Tarazona
Mar 18, 2011·Journal of Innate Immunity·Rebekka WehnerMarc Schmitz
Apr 28, 2011·Seminars in Immunopathology·Michael Campoli, Soldano Ferrone
Jun 7, 2011·Cancer Immunology, Immunotherapy : CII·Beatriz Sanchez-CorreaRaquel Tarazona
Jun 17, 2011·Human Pathology·Kristopher McKayKim M Hiatt
Jul 5, 2011·Cancer Research·Magali TermeLaurence Zitvogel
Aug 10, 2011·Proceedings of the National Academy of Sciences of the United States of America·Sandra Lopez-VergèsLewis L Lanier
Aug 17, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maria R ParkhurstSteven A Rosenberg
Oct 25, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Benyamin RosentalAngel Porgador

❮ Previous
Next ❯

Citations

Aug 18, 2016·Cancer Immunology, Immunotherapy : CII·Raquel TarazonaRafael Solana
Jan 6, 2017·Virchows Archiv : an International Journal of Pathology·Francesca Maria Bosisio, Joost J van den Oord
Dec 26, 2017·Frontiers in Immunology·Hassan SadozaiMirjam Schenk
Apr 5, 2019·Oncology Letters·Monica NeaguSabina Zurac
Oct 23, 2016·International Journal of Cancer. Journal International Du Cancer·Guillaume SarrabayrouseAnne Françoise Tilkin-Mariame
Dec 14, 2017·International Journal of Molecular Sciences·Helena Kupcova SkalnikovaPetr Vodicka
Apr 7, 2019·Cancer Immunology, Immunotherapy : CII·Beatriz Sanchez-CorreaRaquel Tarazona
Mar 14, 2017·Evidence-based Complementary and Alternative Medicine : ECAM·Shintaro IshikawaTadashi Hisamitsu
Nov 4, 2020·Cancers·Aintzane ApraizBeatriz Arteta
Mar 4, 2021·Current Oncology·Synat KangLi Yu
Nov 9, 2021·ACS Omega·Katerina ShamalovCyrille J Cohen

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00328861
NCT00720785
NCT00846833
NCT00855452
NCT01750580
NCT01714739
NCT02331875
NCT02459301

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Hans J J van der VlietMark A Exley
Cancer Immunology, Immunotherapy : CII
Constantin N Baxevanis, Michael Papamichail
Seminars in Hematology
Sherif S Farag, Michael A Caligiuri
© 2022 Meta ULC. All rights reserved